CN110325196B - 用于抑制癫痫发作的组合物和方法 - Google Patents

用于抑制癫痫发作的组合物和方法 Download PDF

Info

Publication number
CN110325196B
CN110325196B CN201780086503.7A CN201780086503A CN110325196B CN 110325196 B CN110325196 B CN 110325196B CN 201780086503 A CN201780086503 A CN 201780086503A CN 110325196 B CN110325196 B CN 110325196B
Authority
CN
China
Prior art keywords
mice
seizure
species
bacteria
fed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780086503.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110325196A (zh
Inventor
E·萧
J·矢野
H·王
C·奥尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Priority to CN202411196564.7A priority Critical patent/CN119033822A/zh
Publication of CN110325196A publication Critical patent/CN110325196A/zh
Application granted granted Critical
Publication of CN110325196B publication Critical patent/CN110325196B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201780086503.7A 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法 Active CN110325196B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411196564.7A CN119033822A (zh) 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436711P 2016-12-20 2016-12-20
US62/436,711 2016-12-20
US201762447992P 2017-01-19 2017-01-19
US62/447,992 2017-01-19
PCT/US2017/067548 WO2018119048A1 (en) 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411196564.7A Division CN119033822A (zh) 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法

Publications (2)

Publication Number Publication Date
CN110325196A CN110325196A (zh) 2019-10-11
CN110325196B true CN110325196B (zh) 2024-08-27

Family

ID=62627881

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780086503.7A Active CN110325196B (zh) 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法
CN202411196564.7A Pending CN119033822A (zh) 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411196564.7A Pending CN119033822A (zh) 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法

Country Status (7)

Country Link
US (3) US11129858B2 (https=)
EP (1) EP3558329B1 (https=)
JP (1) JP7166280B2 (https=)
CN (2) CN110325196B (https=)
AU (1) AU2017382197B2 (https=)
CA (1) CA3047397A1 (https=)
WO (1) WO2018119048A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017382197B2 (en) 2016-12-20 2022-12-01 The Regents Of The University Of California Compositions and methods for inhibiting seizures
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
WO2020058979A2 (en) * 2018-09-20 2020-03-26 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral sclerosis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
WO2020076043A1 (ko) * 2018-10-08 2020-04-16 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
JP7431964B2 (ja) * 2020-06-12 2024-02-15 森永乳業株式会社 ミトコンドリア機能改善用組成物
CN113367328B (zh) * 2021-06-11 2023-02-21 无锡市人民医院 一种调节肠道菌群和能量代谢的多阶段生酮饮食配方
KR20240040089A (ko) * 2021-07-20 2024-03-27 위니베르시트카솔리끄드루뱅 보상 조절 장애의 방지 및/또는 치료
WO2023001368A1 (en) * 2021-07-20 2023-01-26 Université Catholique de Louvain Prevention and/or treatment of reward dysregulation disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP2958575B1 (en) * 2013-02-22 2019-04-03 The Regents of The University of California Composition comprising lactobaccilus johnsonii 456 and its use in treating or preventing diseases
KR101445243B1 (ko) * 2014-03-28 2014-09-29 서울대학교산학협력단 장내 세균의 군집과 기능의 변화를 이용한 대사성 및 염증성 질환의 조기진단
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
BR112017024928A2 (pt) * 2015-05-21 2018-07-31 Yeda Research And Development Co Ltd Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica
AU2016268158B2 (en) * 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
AU2017382197B2 (en) 2016-12-20 2022-12-01 The Regents Of The University Of California Compositions and methods for inhibiting seizures
WO2020191002A1 (en) 2019-03-18 2020-09-24 The Regents Of The University Of California Compositions and methods for treating cushing's disease

Also Published As

Publication number Publication date
JP2020502281A (ja) 2020-01-23
WO2018119048A1 (en) 2018-06-28
US12364717B2 (en) 2025-07-22
AU2017382197A1 (en) 2019-07-04
EP3558329C0 (en) 2024-01-31
US20220184144A1 (en) 2022-06-16
EP3558329A4 (en) 2020-07-22
EP3558329B1 (en) 2024-01-31
US11883441B2 (en) 2024-01-30
AU2017382197B2 (en) 2022-12-01
EP3558329A1 (en) 2019-10-30
CN119033822A (zh) 2024-11-29
CA3047397A1 (en) 2018-06-28
US20200384037A1 (en) 2020-12-10
US11129858B2 (en) 2021-09-28
CN110325196A (zh) 2019-10-11
US20240238350A1 (en) 2024-07-18
JP7166280B2 (ja) 2022-11-07

Similar Documents

Publication Publication Date Title
CN110325196B (zh) 用于抑制癫痫发作的组合物和方法
US20210128641A1 (en) Compositions and methods for treating skin and mucous membrane diseases
US12292445B2 (en) Methods of selecting subjects for treatment with metabolomic modulators
JP7798785B2 (ja) 代謝の健康を改善するための細菌株を含む組成物
US10413577B2 (en) Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
BR112019026677A2 (pt) composições compreendendo cepas bacterianas
US20250064882A1 (en) Postbiotic compositions and methods
EP4108260A1 (en) Composition for alleviating pulmonary hypertension, method for predicting prognosis of pulmonary hypertension, method for assisting in determining severity of pulmonary hypertension, and method for assisting in diagnosing pulmonary hypertension
EP3965820A1 (en) Compositions and methods for promoting healthy neural development in an unborn baby
CN111263590A (zh) 具有体力提高作用及抗疲劳作用中的一种以上作用的组合物
JPWO2019092896A1 (ja) アッカーマンシア・ムシニフィラ増殖材
US20220265733A1 (en) Compositions comprising bacterial strains
TWI740057B (zh) 乳雙歧桿菌gkk2之活性物質、含其之組合物及其促進長壽之用途
WO2025038777A2 (en) Probiotics and methods to reduce appetite
EP3976026A2 (en) Compositions and methods for modulating cognitive behavior
WO2021016347A1 (en) Compositions and methods for treating skin infections and other diseases
US20250025516A1 (en) Compositions and methods for inhibiting seizures
US20250295709A1 (en) Postbiotic preparation for preventing or treating obesity
TW202027768A (zh) 包含細菌品系之組成物
WO2026006209A1 (en) Compositions including n-acetyl-d-glucosamine (glcnac) as a prebiotic agent against multiple oral diseases
JP2003238423A (ja) 血中コレステロール低下剤および血中コレステロール低下飲食品
JP2022080787A (ja) アルツハイマー病様症状緩和剤
NZ760637B2 (en) Compositions comprising bacterial strains

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment